349 results about "Viral infection" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

This invention discloses the application of the DNAL1 gene as a target in screening drugs for the prevention and treatment of Zika virus or dengue virus type 2 infection, specifically the application of screening drugs for the prevention and / or treatment of Zika virus or dengue virus type 2 infection with the aim of inhibiting or knocking out the DNAL1 gene. The invention has found that the DNAL1 gene is a key host factor promoting the replication of Zika virus or dengue virus type 2, and that inhibiting the DNAL1 gene through siRNA or knocking out the DNAL1 gene through CRISPR / Cas9 can inhibit the replication of Zika virus or dengue virus type 2. The DNAL1 gene is a potential host factor for flaviviruses, and this invention provides a potential target for the prevention and / or treatment of Zika virus or dengue virus type 2 infection.

The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and / or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of polypeptides.

This invention provides a highly pathogenic feline calicivirus strain, its vaccine, and its applications. The highly pathogenic feline calicivirus was isolated from pathogenic material and identified as a highly pathogenic strain, named FCV CC475, with its cDNA sequence shown in SEQ ID NO.1. This strain exhibits strong pathogenicity, causing infected animals to develop symptoms such as fever, paw pad ulcers, and dehydration by day 3 post-infection; the viral load after 5 generations is 10. 9.80 TCID 50 / ml. This strain produces high antibody titers after immunization of cats and rabbits, demonstrating good immunogenicity. Therefore, this highly pathogenic feline calicivirus has broad application prospects in the preparation of feline calicivirus infection vaccines, diagnostic reagents, or therapeutic drugs.

This invention involves, among other things, elements that stimulate an immune response. Which includes: a) one or more antigens of Avibacterium paragallinarum and One or more antigens of avian brain and spinal cord rhizomatous virus and one antigen. or more of avian porcine ... Furthermore, this invention relates to a method for immunizing animals which includes administration. The animal drug contains components that stimulate the immune response of this invention; moreover, This invention relates to a method of treating or preventing clinical signs caused by Avibactericum. Paragallinarum, a viral infection that causes encephalitis and spinal cord inflammation in birds and avian pox virus in animals. Essential, a method that involves administering medication to animals in effective dosages as a form of treatment. The components that stimulate an immune response are consistent with this invention;

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

A single-domain antibody (sdAb) which binds to head domain of VP6 derived from a human rotavirus A and has neutralization activity against different the rotavirus A types.

Disclosed herein are broad-spectrum antiviral compounds that can prevent or treat disorders related to RNA viral infections. Also disclosed are methods and composition for treating RNA viral infections, including symptoms of the RNA viral infections. The methods, for example, can include administering pharmaceutical compositions comprising one or more of the compounds disclosed herein to a patient in need.

A safe access method, a safe access device, a safe access electronic apparatus and a safe access storage media for external storage devices are provided. By reporting and processing without relying on real-time network connections, and still maintaining effective management of access to portable external storage devices even when there is no network or the network is unstable, thereby reducing potential risks and avoid frequent returns due to risky hardware and reduce the burden of network communications in the enterprise, immediately being disabled the portable external storage device once a digital certificate to be verified is found to be non-compliant, reducing a chance of spreading virus infection for improving the efficiency of information security management through quick response, and destroying the digital certificate to be verified to prevent the certificate from being stolen by others after confirming the safety of the external storage device, thus further ensuring the company's data security, the system and the method can effectively reduce misjudgment and ban of legitimate hardware through verification of digital certificates, and can achieve the effect of reducing the inconvenience caused by users frequently disabling legitimate devices.

A method is provided for treating and / or inhibiting a coronavirus infection. The method includes administering to a subject who has, or is at risk of developing, said infection, an amount of an anionic lipid or related compound that is effective to inhibit said infection, wherein the anionic lipid has a hydrophobic portion, a negatively charged portion, and an uncharged, polar portion.

This invention discloses a method for inhibiting Tamdy virus infection and the use of TCP1 inhibitors. Specifically, this invention discloses a method for inhibiting Tamdy virus (TAMV) infection of host cells, the method comprising the step of reducing or inhibiting the expression level and / or activity of the TCP1 gene or its encoded protein in host cells, wherein the reduction or inhibition of the expression level and / or activity of the TCP1 gene or its encoded protein is achieved by methods selected from the group consisting of: gene mutation, gene knockout, gene interruption, RNA interference technology, gene editing technology, introduction of inhibitors of genes or proteins, or combinations thereof.

To provide treatment of chemosensory dysfunction from a coronavirus infection.SOLUTION: Disclosed herein are methods of treating a taste and smell disorder caused by a viral infection in a subject, comprising administering to the subject a phosphodiesterase inhibitor. Also disclosed herein are methods of treating taste and smell loss from COVID-19 by administering a phosphodiesterase inhibitor to a subject in need thereof.SELECTED DRAWING: None

The present disclosure provides a vaccine composition that comprises an Epstein Barr Virus (EBV) polypeptide and a liposomal adjuvant, and methods of inducing an immune response to an Epstein Barr Virus (EBV) or methods of preventing infection of or reducing the likelihood of infection by an Epstein Barr Virus (EBV) using the compositions, or a combination of the EBV polypeptide and the liposomal adjuvant.

The present application relates to a crystal form of a compound of formula (I) and a preparation method and application thereof. Specifically, the present application provides a crystal form of a compound of formula (I), which has good stability, good drug efficacy, and good safety, and can be used for preparing a drug for treating or preventing feline transmissible enteric disease virus infection or coronavirus infection caused diseases.

The present invention relates to a novel crystalline form of a helicase-primase inhibitor compound, and to pharmaceutical compositions comprising the novel crystalline form, to methods of production of the novel crystalline form, to the crystalline form in medicine and for use in the treatment of herpes viral infections.

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for treating respiratory viral illnesses, such as COVID-19.

The application provides a dengue virus protection and mosquito vector control antigen composition and application thereof. The antigen composition comprises a combination of dengue virus type 1-4 envelope protein domain III polypeptide and Aedes aegypti midgut mucin AaMuc1 antigen polypeptide; the amino acid sequences of the dengue virus type 1-4 envelope protein domain III polypeptide are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4; and the amino acid sequence of the Aedes aegypti midgut mucin AaMuc1 antigen polypeptide is shown as SEQ ID NO. 5. The prepared vaccine can induce the body to produce neutralizing antibodies against dengue virus type 1-4, achieve the protection of human body from dengue virus infection, induce the production of active antibodies targeting Aedes aegypti midgut mucin 1, inhibit and kill the dengue virus transmission vector Aedes aegypti, and achieve the dual prevention and control of dengue fever from two dimensions of infection prevention and transmission interruption.

This invention provides a recombinant conjugate protein against EBV virus and its application. The recombinant conjugate protein is a conjugate of recombinant protein HBc-SC and recombinant EBV antigen protein. In the recombinant conjugate protein, the molar ratio of recombinant protein HBc-SC to recombinant EBV antigen protein is 1:1 to 1:12. The amino acid sequence of the recombinant protein HBc-SC is shown in SEQ ID NO:1. The recombinant EBV antigen protein includes a recombinant gHgL fragment and a tag sequence. The recombinant gHgL fragment is shown in SEQ ID NO:3. The tag sequence is shown in SEQ ID NO:5, and the tag sequence is located at the C-terminus of the recombinant EBV antigen protein. The recombinant conjugate protein provided by this invention can induce strong humoral immunity, significantly increasing neutralizing antibody titers in epithelial cells and B cells, making it an excellent candidate vaccine for preventing EBV virus infection.

The present invention provides isolated polypeptides capable of specifically binding to a protein target selected from LGALS9, CRP, BTLA, SAA, EGF, or FGA, or to a peptide thereof, especially under urinary conditions, which may be used for predicting in a urine sample of a subject suspected of having an infection whether the infection is a bacterial infection or a viral infection. The present invention further provides methods of diagnostics and treatment using the isolated polypeptides, and suitable diagnostic kits.

The present disclosure relates to a BCG based therapeutic agent using a BCG strain that overexpresses the STING agonist, c-di-AMP. This BCG strain, called BCG-disA-OE, enhances the elevated trained immunity of macrophages and promotes early anti-viral Type I interferon responses in a subject, providing protection against viral infections such as primary respiratory infections and SARS-CoV-2 infection.

This invention relates to the field of biotechnology, and in particular to an antigenic epitope peptide, product, and application for detecting antibodies produced by porcine deltacoronavirus infection. This invention identified short peptide epitopes in PDCoV longitudinal challenge serum samples, obtaining 12 short peptides, which were then prepared into a porcine deltacoronavirus antibody detection kit. Finally, six field serum samples were selected for antibody detection, and the effectiveness was verified using a virus neutralization experiment. The results showed that the porcine deltacoronavirus antibody detection kit provided by this invention is effective. Furthermore, the porcine deltacoronavirus antibody detection kit provided by this invention, as a novel detection method, improves sensitivity and specificity while simultaneously providing multiple detection results, namely, determining whether viral infection has occurred, identifying the stage of infection, and achieving DIVA (Differentiation, Infection, and Variability) analysis.

The present disclosure is directed to compositions comprising between 50% and 95% weight per weight (w / w) of acetic acid, between 0.1% and 5% (w / w) of butyric acid or a derivative thereof, and between 0.1% and 5% (w / w) of Quercetin or a derivative thereof. Further, methods of use such as for the treatment and prevention of a medical condition associated with cancer, inflammatory diseases or disorders, metabolic disorders, obesity, diabetes, high blood pressure, vascular diseases, viral infection, and any combination thereof, in a subject in need thereof are also provided.

Disclosed are monoclonal antibodies and antigen binding fragments thereof that specifically bind to Nipah virus (NiV) F or G protein. In several examples, the antibodies and antigen binding fragments are cross-reactive with other Henipavirus F or G proteins, such as Hendra virus (HeV) F or G proteins. Also disclosed is the use of these antibodies and antigen binding fragments for inhibiting a Henipavirus infection, such as a NiV and / or HeV infection. In addition, disclosed are methods for detecting Henipavirus, such as NiV or HeV in a biological sample, using the disclosed antibodies and antigen binding fragments.

The application provides a one-step RT-PCR detection kit for detecting porcine getah virus infection and application thereof, and belongs to the technical field of virus detection. The application provides a one-step RT-PCR detection kit for detecting porcine getah virus (GETV) infection and application thereof, wherein the kit contains a pair of specific primers for detecting the getah virus. The kit has good detection result specificity, and has no cross reaction with main members of pig diseases and common pig, cattle and sheep pathogens; the kit has high sensitivity, and the sensitivity for detecting plasmid standard products and GETV cell toxins is 5.9 copies and 0.3 TCID 50 respectively; the kit is rapid, sensitive, simple, low in cost, reverse transcription and PCR are performed in one reaction tube, and the pollution opportunity is reduced.

Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.

Use of MMPD for the preparation of a medicament for inhibiting porcine epidemic diarrhea virus (PEDV) infection in vitro.

COMBINED PLANT COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 Abstract The present invention is directed to a compound herbal composition when used in treating COVID-19, comprising: Radix angelicae dahuricae; Herba moslae; Flos lonicerae japoni- cae; Semen sojae preparatum; Fructus momordicae; Rhizoma zingiberis recens; Radix platycodonis; Rhizoma phragmitis; Rhizoma imperatae; Fistular onion stalk; Radix et rhizome glycyrhizae; Fructus evodiae; Fructus alpiniae oxyphyllae; Fructus psoraleae; Fructus corni; Flower of Hyacinth Bean; Semen cuicis; and optionally together with up to about 1 wt% of one or more pharmaceutically acceptable excipients. COMBINED PLANT COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 20 26 20 51 87 30 J un 2 02 6 C O M B I N E D P L A N T C O M P O U N D S F O R U S E I N T H E T R E A T M E N T O F V I R A L I N F E C T I O N S I N C L U D I N G C O V I D - 1 9 2 0 2 6 2 0 5 1 8 7 3 0 J u n 2 0 2 6 A b s t r a c t

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza virus neuraminidase (NA) and can neutralize an influenza virus infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an influenza infection.

The present invention relates to a composition for preventing and treating viral infection of the family of African swine fever viruses, in particular, a composition for treating, inhibiting and / or preventing viral infection of the family of African swine fever viruses (Asfaraviridae), preferably African swine fever virus, characterized in that the composition comprises one or more medium-chain fatty acids (MCFAs) and / or derivatives thereof.